Stryker Corp. (NYSE:SYK) picked a former Johnson & Johnson (NYSE:JNJ) executive to lead its nascent neurotechnology and spine group.
NxStage Medical Inc.
Dialysis maker NxStage gives CEO Burbank a raise
NxStage Medical Inc. (NASDAQ:NXTM) handed out pay raises to several members of its leadership team after a year that saw the dialysis maker boost sales 20 percent and cut its net losses.
Intraoperative defibrillator testing under scrutiny | Research roundup
Here’s a roundup of recent clinical trial and scientific study news:
NxStage and Fresenius square off in home dialysis market
Fresenius Medical Care Holdings Inc. (NYSE:FMS) is getting into the home dialysis game with the release of a more portable version of its in-center 2008-series hemodialysis machines for patients with acute kidney failure.
Fresenius, the world’s largest dialysis maker said that it received Food & Drug Administration clearance for its 2008K@home dialysis machine and will have it on the market during the early summer, according to a prepared statement.
Alere’s losses break the billion mark | Earnings roundup
MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.
Here’s a quick rundown of a few releases over the past couple days:
Personnel moves: NxStage names Joseph Turk President, North America
NxStage extends distribution footprint
NxStage Medical Inc.’s (NSDQ:NXTM) Medisystems division signed a Tennessee-based medical products supplier to expand its sales reach.
NxStage, which develops home hemodialysis products, has posted rising sales and decreasing losses in recent quarters.
Clinical Update: A gap in the FDA’s oversight of medical device trials
There’s a “potentially troubling gap” in the Food & Drug Administration’s oversight of medical device clinical trials, according to the Wall Street Journal — the federal watchdog agency doesn’t inspect device-making plants during trials.
The Journal, citing the failed clinical trial of an Aptus Endosystems Inc. stent graft, said the lack of oversight means “hundreds of participants in clinical-trial studies of medical devices may be at risk of receiving faulty devices.”
NxStage Medical reels in $66 million in stock offering
NxStage Medical Inc. (NSDQ:NXTM) grossed $66.1 million from the sale of 3.2 million shares of its common stock.
The Lawrence, Mass.-based home hemodialysis products maker sold the shares for $20.65 each, according to a filing with the federal Securities & Exchange Commission. NXTM shares, which closed at $21.38 yesterday, were trading at $20.67 in early-afternoon activity, down 3.4 percent.
NxStage Medical trends positive again during Q2
NxStage Medical Inc. (NSDQ:NXTM) took another leap along the path to profitability during the second quarter, posting a 20.9 percent revenues increase and shaving losses by 34 percent.
The Lawrence, Mass.-based home hemodialysis products maker reported net losses of $8.3 million, or 17 cents per diluted share, on sales of $44.0 million during the three months ended June 30. That compares with net losses of $12.5 million, or 27 cents per diluted share, during the same period last year.
NxStage and Spindial ink Italian distribution deal
NxStage Medical Inc. (NSDQ:NXTM) broadened its stake in the Italian dialysis market with a Spindial S.p.A. distribution deal.
The Lawrence, Mass.-based company inked a five-year agreement for renal care product distributor Spindial S.p.A. to sell NxStage’s System One hemodialysis treatment system in Italy.